Volltext-Downloads (blau) und Frontdoor-Views (grau)

Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry

  • Background: Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have shown good efficacy in migraine prophylaxis. However, a subset of patients does not respond to the first mAb treatment and switches among the available mAbs. The goal of this study is to characterize the switching pattern of migraine patients treated with anti-CGRP(-receptor, -R) mAbs, and to describe the headache burden of those who did not switch, switched once, and switched twice. Methods: This study used real world data from the NeuroTransData Cohort, a registry of migraine patients treated at outpatient neurology clinics across Germany. Patients who had received at least one anti-CGRP(-R) mAb were included. Headache diaries were collected at baseline and during treatment, along with quality of life measures every three months. Results were summarized for the subgroups of patients who did not switch and those with one and two switches. Results: Of the 655 eligible patients, 479 did not switch, 135 switched once, 35 twice, and 6 three or more times. The ≥ 50% response rates for monthly migraine days were 64.7%, 50.7%, and 25.0% for the no switch, one switch, and two switches groups in their last treatment cycles, respectively. Quality of life measures improved for the no switch and one switch groups, but not for the two switches group. Conclusion: Patients who switched among anti-CGRP(-R) mAbs during the course of their treatment still benefited overall but to a lesser extent than those who did not switch. Treatment response in patients who switched twice was markedly lower compared to the no switch and one switch subgroup. Keywords: Calcitonin-gene-related peptide; Migraine; Monoclonal antibody; Prophylaxis; Real-world experience.
Metadaten
Author:Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, Peter SchanbacherORCiD, Viola Tozzi, Monika Köchling, Uwe Reuter, Bianca Raffaelli
URN:https://urn:nbn:de:bsz:fn1-opus4-110706
DOI:https://doi.org/10.1186/s10194-024-01790-7
ISSN:1129-2377
Parent Title (German):Journal of Headache and Pain
Contributor(s): NTD Study Group
Document Type:Article (peer-reviewed)
Language:German
Year of Completion:2024
Release Date:2024/11/29
Tag:Calcitonin-gene-related peptide; Migraine; Monoclonal antibody; Prophylaxis; Real-world experience
Volume:25.2024
Issue:1
Article Number:90
Page Number:10
Open-Access-Status: Open Access 
 Gold 
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International